The study aims to assess the feasibility of a population-based approach to evaluating the effects of screening for prostate cancer in first-degree male relatives (FDRs) of patients diagnosed with prostate cancer at age ⩽65 years in the UK and to study the impact of PSA testing on referral for biopsy. Here, KLK3 is linked to prostate cancer.